German market stats updated at Medica
This article was originally published in Clinica
Executive Summary
German medical technology manufacturers have increased their exports by 70% to €11.7bn ($14.6bn) in the last five years, and exports now account for 64% (54% in 2003) of these companies’ sales. These are among the facts and figures published by Spectaris (Berlin) in a book, released during this year’s Medica trade fair, entitled “Die deutsche Medizintechnik-Industrie”. Whenever German healthcare is mentioned, it tends to be mainly in connection with rising costs and insurance premiums, said the industry association’s head, Sven Behrens. A far better theme would be the cost-benefit ratio of medtech, and its potential benefit to the German economy, he said. “Society is ageing, and it needs innovative medtech products and services; hospitals that do not invest in modern medtech systems will not be able to meet the future demand,” he stressed. The 90-page facts and stats publication can be ordered at www.spectaris.de
You may also be interested in...
The Sustainability Stakes Are Rising: ‘We Cannot Recycle Our Way Out Of This’
The journey to Net Zero, described as ‘the defining issue of our time,’ will get harder in the coming decade. Failure to keep up the pressure will result in more long-term health conditions, increasing deaths and higher costs. The UK NHS is a Net Zero exemplar globally, but without a systemic approach, its compliance efforts could stutter.
UK Life Sciences Cautiously Upbeat For Investment Year Ahead – BioWales 2024
Favorable UK biopharma investment trends have been reported by the BioIndustry Association, but can medtech and healthtech share in the positivity? A roundtable at the BioWales in London 2024 event framed the outlook for non-pharma players.
An Ecosystem For Medtech Funding And Innovation Support – BioWales 2024
Creo Medical and Clinithink are among the healthtech innovators who have benefited from funding and advisory support offered by the Development Bank of Wales. All three gave a take on the current funding environment at BioWales in London 2024.